



1F-689-T025

Monoclonal Antibody to CD23 Fluorescein (FITC) conjugated (25 tests)

Clone:	EBVCS-5
Isotype:	Mouse IgG1
Specificity:	The mouse monoclonal antibody EBVCS-5 recognizes an epitope located in the stalk region of human low affinity IgE receptor (CD23) between the 37 and 25 kDa cleavage sites.
Regulatory Status:	RUO
Immunogen:	EBV-transformed human cells
Species Reactivity:	Human
Preparation:	The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC and adjusted for direct use. No reconstitution is necessary.
Storage Buffer:	The reagent is provided in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide.
Storage / Stability:	Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Usage:	The reagent is designed for Flow Cytometry analysis of human blood cells using 4 µl reagent / 100 µl of whole blood or 10 ⁶ cells in a suspension. The content of a vial (0.1 ml) is sufficient for 25 tests.
Expiration:	See vial label
Lot Number:	See vial label
Background:	CD23 (Fc epsilon RII), the low affinity IgE receptor, is a 45 kDa type II membrane glycoprotein expressed more or less on eosinophils, follicular dendritic cells, Langerhans cells, mature B cells (mainly upon activation), EBV-transformed lymphoblasts, monocytes, and subpopulation of platelets. A soluble form of 37 kDa and other its fragments were also described. CD23 mediates IgE-dependent cytotoxicity by eosinophils and macrophages, and downregulates IgE secretion in response to high levels of IgE, involving release of pro-inflammatory cytokines.
References:	*Ling NR, Stevenson FK, Brown B: Urinary excretion of CD23 antigen in normal individuals and patients with chronic lymphocytic leukaemia (CLL). Clin Exp Immunol. 1991 Dec;86(3):360-6. *Yamaoka KA, Arock M, Issaly F, Dugas N, Le Goff L, Kolb JP: Granulocyte macrophage colony stimulating factor induces Fc epsilon RII/CD23 expression on normal human polymorphonuclear neutrophils. Int Immunol. 1996 Apr;8(4):479-90. *Belleau JT, Gandhi RK, McPherson HM, Lew DB: Research upregulation of CD23 (FcepsilonRII) expression in human airway smooth muscle cells (huASM) in response to IL-4, GM-CSF, and IL-4/GM-CSF. Clin Mol Allergy. 2005 May 20;3:6. *Byrd JC, O'Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J, Molina A, Leigh B, Harris S: Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4448-55. *Rumi C, Rutella S, Leone G, Bonini S: Fc-RII/CD23 receptor on circulating human eosinophils. Blood. 1998 Apr 1;91(7):2621-2.

For laboratory research only, not for drug, diagnostic or other use.



Antibodies

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.

For laboratory research only, not for drug, diagnostic or other use.

EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic
Tel: +420 261 090 666 | Fax: +420 261 090 660 | orders@exbio.cz | www.exbio.cz